Windlas Biotech Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹448-₹460
- Lot size
- 30 shares
- Issue amount
- ₹402 cr
- Total subscription
- 0×
- Opens
- 4 Aug 2021
- Closes
- 6 Aug 2021
- Allotment
- 11 Aug 2021
- Listing
- 16 Aug 2021
Offer at a glance
Issue overview
- Issue size
- 87,29,023 shares
- Face value
- ₹5 per share
- Minimum investment
- ₹13,440
- Fresh issue
- ₹165 cr
- Offer for sale
- ₹237 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹13,800
- Issue type
- Bookbuilding IPO
- Shares before issue
- 1,82,07,419
- Shares after issue
- 2,17,94,375
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 30 | ₹13,800 |
| sHNI | 15 | 450 | ₹2,07,000 |
| bHNI | 73 | 2,190 | ₹10,07,400 |
Share reservation
Subscription & GMP
Subscription by category
Subscription figures are awaiting publication.
GMP history
Financial performance
Company financials
In Lakhs · Reported periods may include interim results.
Company information
Company profile
Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.
Strengths
- Leading CDMO Player: Top company in India’s pharmaceutical formulation CDMO segment.
- Therapeutic Focus: Strong emphasis on chronic therapy products.
- Advanced Facilities: State-of-the-art manufacturing units in Dehradun, Uttarakhand.
- Experienced Leadership: Professional promoters supported by a skilled senior management team.
- Innovative Portfolio: Offers complex generic products.
- Strong Financials: Demonstrates a robust track record of financial performance.
Promoters
Ashok Kumar Windlass
Hitesh Windlass
Manoj Kumar Windlass
AKW WBL Family Pvt Trust
Registrar & documents
Lead manager
Dam Capital Advisors Limited, IIFL Capital Services Limited, SBI Capital Markets Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
40/1, Mohabewala Industrial Area, Dehradun, 248110
+91 135 6608000
[email protected]Company website ↗Understanding WINDLAS IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.